Oncology-Based In Vivo CRO Market- Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Market Overview

The Oncology-Based In Vivo CRO Market is projected to grow from USD 1,114.5 million in 2024 to USD 1,914.91 million by 2032, with a compound annual growth rate (CAGR) of 7% during the forecast period.

The market growth is primarily driven by the increasing prevalence of cancer, one of the leading causes of death globally. Furthermore, the rising focus on targeted therapies and immuno-oncology treatments necessitates the use of specialized in vivo research models to evaluate the efficacy and safety of emerging drug candidates. The growing trend towards personalized medicine, which tailors treatment options based on individual patient profiles, also supports the demand for in vivo testing services. Additionally, collaborations between pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) are enhancing research capabilities and accelerating the drug development process, which is helping shorten the time-to-market for new oncology therapies.

Market Drivers

Advancements in Targeted and Immuno-Oncology Therapies

The shift towards personalized and targeted therapies is a key driver in the oncology-based in vivo CRO market. In vivo models are essential for evaluating the efficacy and safety of new therapies, such as immuno-oncology treatments. For example, drugs like Bristol-Myers Squibb’s Opdivo (nivolumab), which targets specific molecules involved in cancer growth, require tailored preclinical testing using specialized in vivo models. As the adoption of these targeted therapies grows, the demand for in vivo testing services increases, which in turn accelerates the growth of the CRO market.

Market Challenges Analysis

High Cost of In Vivo Testing

A significant challenge in the oncology-based in vivo CRO market is the high cost associated with in vivo testing. The specialized facilities, animal care requirements, advanced equipment, and the long duration of these studies contribute to the high costs. These expenses can be a barrier, especially for smaller biotechnology firms and startups that may have limited budgets. This limitation can slow innovation and hinder smaller players from accessing necessary in vivo CRO services, potentially delaying progress in oncology drug development.

Market Segmentation

By Indication

Solid Tumors

Syngeneic Model

Patient Derived Xenograft (PDX)

Blood Cancer

Syngeneic Model

Patient Derived Xenograft (PDX)

Xenograft

Other Indications

Syngeneic Model

Patient Derived Xenograft (PDX)

Xenograft

By Region

North America

The U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

Southeast Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Key Player Analysis

Charles River Laboratories

Covance (Labcorp Drug Development)

Envigo

Pharmaron

WuXi AppTec

Celerion

Kezar Life Sciences

Taconic Biosciences

Syngene International

CROMSOURCE